Cancer Research Technology
Log in Register
Menu

Mouse fibrosarcoma Luciferase2 mStrawberry VEGF120 Cell Line

Invented by Prof Gillian Tozer at University Of Sheffield

Info

Catalogue Number 152853
Antigen/Gene or Protein Targets VEGF120
Parental Line MEF
Synonyms VEGF-A, VEGF120, VEGF164, VEGF188
Host Mouse
Tissue Embryo
Disease Keywords Cancer
Model Immortalised Line
Relevance Mouse fibrosarcoma cell lines that are capable of expressing all vascular endothelial growth factor (VEGF) isoforms (control) or only single isoforms of VEGF (VEGF120, VEGF164, or VEGF188) were developed under endogenous VEGF promoter control.

The original rationale for the development of these cell lines relates to the fact that tubulin-binding vascular-disrupting agents (VDA) are currently in clinical trials for cancer therapy but the factors that influence tumour susceptibility to these agents are poorly understood. Researchers evaluated the consequences of modifying tumour vascular morphology and function on vascular and therapeutic response to combretastatin-A4 3-O-phosphate (CA-4-P), which was chosen as a model VDA. The cell lines themselves could be potentially valuable for the commercial/pharmaceutical industry.
Production Details Using Cre/Lox technology, mice expressing all or only single isoforms of VEGF, known as Vegfa120/120, Vegfa164/164, and Vegfa188/188 mice were developed. Primary fibroblasts were isolated from mouse embryos that were produced by heterozygous breeding pairs of mice expressing single or all isoforms of vascular endothelial growth factor-A (VEGF-A) on Swiss background. Fibroblasts were immortalized and oncogenically transformed by retroviral transduction with SV40 and HRAS using Lipofetamine 2000 (characterised in Tozer et al., 2008. Cancer Res; 68: (7)). mStrawberry positive cells were processed through 3 rounds of FACS (BD FACS ARIA). Bioluminescence output for each cell (p/s/cell) was measured through playing serial dilutions of the fibrosaroma-LS cell lines using complete medium (100ul) which had 50 ul D-Luciferin (0.6 mg/ml) added just before IVIS LUmina II measurement. Secondary development has modified the original cell lines to express Luciferase2 and mStrawberry to allow optical imaging of tumour deposits.
Conditional No
Research Area Cancer, Cell Signaling & Signal Transduction, Developmental Biology, Drug Discovery & Development, Metabolism
Growth/Phenotype Keywords Adherent
Recommended Growing Conditions High glucose DMEM (Invitrogen) medium, L-glutamine, FCS, G-418 and puromycin. antibiotics G-418 and puromycin
Cellosaurus ID CVCL_HG19

References

There are 2 reference entries for this reagent.

View All References

References: 2 entries

Differential Expression of VEGFA Isoforms Regulates Metastasis and Response to Anti-VEGFA Therapy in Sarcoma. English et al. 2017. Cancer Res. 77(10):2633-2646. PMID: 28377452.

Differential Expression of VEGFA Isoforms Regulates Metastasis and Response to Anti-VEGFA Therapy in Sarcoma.

Europe PMC ID: 28377452


Add a reference

References: 2 entries

Differential Expression of VEGFA Isoforms Regulates Metastasis and Response to Anti-VEGFA Therapy in Sarcoma. English et al. 2017. Cancer Res. 77(10):2633-2646. PMID: 28377452.

Differential Expression of VEGFA Isoforms Regulates Metastasis and Response to Anti-VEGFA Therapy in Sarcoma.


Add a reference